One Man, $20,000, and a Dozen AI Tools: How Medvi Hit $401 Million in Its First Year

Sam Altman predicted in 2024 that artificial intelligence would make a one-person billion-dollar company possible. On April 2, 2026, The New York Times published a profile suggesting it has already happened.

Matthew Gallagher, a 41-year-old self-taught programmer in Los Angeles, launched a telehealth company called Medvi in September 2024 with $20,000 and more than a dozen AI tools. In its first full calendar year, the company generated $401 million in revenue with a 16.2 percent net profit margin — roughly $65 million in profit. Medvi's only employee is Gallagher's younger brother, Elliot. The company is now on track for $1.8 billion in sales in 2026, generating more than $3 million per day.

The New York Times verified the financials directly.

How He Built It

Gallagher did not build a medical company. He built a marketing and distribution layer on top of existing medical infrastructure, using AI to replace the functions that would normally require dozens or hundreds of employees.

ChatGPT, Claude, and Grok wrote the code for Medvi's software platform and website. Midjourney generated the visual assets. Runway produced video advertisements. ElevenLabs handled customer service calls through AI-generated voice. Custom AI agents tied the entire operation together — from performance analytics to customer acquisition workflows.

The medical side was entirely outsourced. CareValidate, an Atlanta-based startup, provided the telehealth-in-a-box infrastructure: a network of licensed doctors, prescription software, and compliance systems. OpenLoop Health handled pharmacy fulfillment, shipping, and patient management. Medvi's role was branding, marketing, and customer acquisition — the layer where AI tools provide the most leverage for a single operator.

The product itself was straightforward: GLP-1 weight-loss drugs delivered to consumers' doors at $179 per month, without requiring an in-person doctor visit. The timing was perfect. American demand for affordable GLP-1 drugs was surging, and Gallagher arrived with a clean consumer brand and aggressive digital marketing at exactly the right moment.

The Numbers in Context

To appreciate Medvi's efficiency, compare it with Hims & Hers Health, the publicly traded telehealth company operating in the same market. Hims & Hers reported $2.4 billion in revenue in 2025 with 2,442 employees and a 5.5 percent net margin. Medvi achieved $401 million with two people and a 16.2 percent margin — nearly three times the profitability per revenue dollar with a fraction of one percent of the headcount.

Gallagher grew up in financial hardship, moving between motels and at one point living in a car with his family. He taught himself to code and previously ran a watch subscription company called Watch Gang that employed 60 people but never turned a profit. That experience made him deeply skeptical of traditional hiring. When he built Medvi, he treated every dependency as a service, not a position. Doctors, pharmacies, shipping, legal, accounting — all outsourced, either to platforms or to AI.

The Vulnerabilities

The story is not without significant caveats. In March 2026, the FDA issued warning letters to 30 telehealth companies — Medvi among them — for making misleading claims about compounded GLP-1 drugs. The FDA has determined that the semaglutide drug shortage is resolved, which narrows the legal basis for selling compounded versions. The Department of Justice has already been referred enforcement cases against some telehealth operators in this space.

Medvi holds no proprietary technology, no licensed physician network, no pharmacy infrastructure, and no exclusive supplier relationships. Any operator with marketing fluency and access to CareValidate or OpenLoop could theoretically replicate the model. The defensible layer, to the extent one exists, is execution speed and brand recognition.

There is also the single point of failure problem. Gallagher once broke his own website while hiking, losing an estimated 200 customers in a single hour because no one else could fix it. His solution was to hire two contract engineers — not full-time employees. The reluctance to add headcount is a philosophy, but it is also a structural risk.

Mubboo's Take

Medvi is a proof of concept, not a template. What Gallagher demonstrated is that AI tools have compressed the operational requirements of building a consumer brand to the point where a single technically fluent founder can reach hundreds of millions in revenue. That compression is real, and it applies far beyond telehealth — including how consumers compare and evaluate the products these new AI-built companies sell.

But the story also illustrates the limits of pure AI leverage. The product Medvi sells — compounded GLP-1 drugs marketed through aggressive digital advertising — sits in a regulatory gray zone that the FDA is actively closing. A business model built on execution speed in a compliance-sensitive industry is inherently fragile, no matter how sophisticated the AI stack.

For consumers, the lesson is that AI-powered businesses can now scale to massive size before regulatory frameworks catch up. That gap between capability and oversight is where both innovation and risk concentrate. Comparison platforms and independent consumer guides exist precisely to help people navigate that gap — to distinguish between genuine value and speed-of-execution without substance.